Physician profile
Steven A Agemy
NPI 1245541671
$2,997.47
in general payments reported to CMS, 2019-2025
17 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 77% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2021: $25.00 · 2022: $216 · 2023: $352 · 2024: $858 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $601.79 | 2023-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $345.53 | 2023-2025 | Ozurdex |
| Amgen INC. | $296.26 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $238.01 | 2019 | |
| Apellis Pharmaceuticals, INC. | $230.24 | 2023-2025 | Syfovre |
| Alcon Vision LLC | $193.82 | 2019-2025 | Hydrus Microstent |
| Biotissue Holdings INC. | $175.39 | 2021-2024 | |
| Astellas Pharma US INC | $167.37 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $133.74 | 2023-2024 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $127.85 | 2022-2025 | Acthar |
| Coherus Oncology, INC. | $124.70 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $116.96 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $75.69 | 2025 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $67.82 | 2023-2025 | Xipere, Lotemax Sm, Visudyne |
| Genentech USA, INC. | $58.76 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $22.31 | 2023 | Flarex |
| Eyepoint US, INC. | $21.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Agemy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.